ICYMI, some of this week’s featured content includes an exclusive interview about hyperhidrosis, and articles on a new the ACAAI annual scientific meeting this weekend, clascoterone cream, and more.
Sun Pharma has announced that their Winlevi 1% cream is now available in the US to treat acne vulgaris in patients 12 years and older.
Investigators noted the treatment method was well tolerated in patients who could not safely use oral cyclosporine.
In this episode of DermView, Adelaide Hebert, MD, highlights both emollients and moisturizers. She also talks about bathing and how often a child should bathe if they have eczema.
We sit down in a video interview with David Pariser, MD, FACP, FAAD, the secretary and founding member of the International Hyperhidrosis Society to discuss hyperhidrosis identifiers and treatments in honor of Hyperhidrosis Awareness Month.
The study examines the impact of antirheumatic treatment on pregnancy outcomes in women with psoriatic arthritis.
Jonathan M. Spergel, MD, PhD, FACAAI discusses what there is to look forward to at the ACAAI conference and what he's highlighting at the event.
In this video, Ama Alexis, MD, tells us what we have to look forward to at the ACAAI conference this week.
In this week’s Pointers with Dr Portela, the 208SkinDoc honors the end of Eczema Awareness Month with a video explaining the skin condition.
Sessions with a laser focus on dermatologic issues ranging from new JAK inhibitors to disparities in atopic dermatitis anchor the opening day of the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.
In this video interview, Jeff Yu, MD, talks about what he's looking forward to at the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.
In this episode, we dive into the background of the “The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas.” Adam Friedman, MD, and Misty Eleryan MD, MS, describe their process to creating this new dermatologic resource.
Several doctors were recognized at the American College of Allergy, Asthma, & Immunology annual scientific meeting held November 4 to 8 in New Orleans, Louisiana.
Incyte announced that ruxolitinib cream has received validation for its European marketing authorization application from the European Medicines Agency.
There are several fine nuances and differences in the presentation of atopic dermatitis in patients with skin of color that differ from the presentation seen in patients with lighter skin types. As such, clinicians should be aware of these differences to improve the treatment and management of AD in patients with skin of color.